BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 28625632)

  • 21. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.
    Ahn JS; Ahn YC; Kim JH; Lee CG; Cho EK; Lee KC; Chen M; Kim DW; Kim HK; Min YJ; Kang JH; Choi JH; Kim SW; Zhu G; Wu YL; Kim SR; Lee KH; Song HS; Choi YL; Sun JM; Jung SH; Ahn MJ; Park K
    J Clin Oncol; 2015 Aug; 33(24):2660-6. PubMed ID: 26150444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
    BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data.
    Kim E; Biswas T; Bakaki P; Dowlati A; Sharma N; Machtay M
    Pract Radiat Oncol; 2016; 6(5):e163-e169. PubMed ID: 27142494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
    Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
    J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
    Rajappa S; Sharma S; Prasad K
    Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature.
    Tsujino K; Kurata T; Yamamoto S; Kawaguchi T; Kubo A; Isa S; Hasegawa Y; Ou SH; Takada M; Ando M
    J Thorac Oncol; 2013 Sep; 8(9):1181-9. PubMed ID: 23883782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P; Ciuleanu TE; Cernea D; Pelau D; Gaal V; Cebotaru C; Guttman T; Todor N; Ghilezan N
    J BUON; 2007; 12(1):33-9. PubMed ID: 17436399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.
    Wang L; Correa CR; Zhao L; Hayman J; Kalemkerian GP; Lyons S; Cease K; Brenner D; Kong FM
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1383-90. PubMed ID: 18929449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone.
    Huang EH; Liao Z; Cox JD; Guerrero TM; Chang JY; Jeter M; Borghero Y; Wei X; Fossella F; Herbst RS; Blumenschein GR; Moran C; Allen PK; Komaki R
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):779-85. PubMed ID: 17418967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy.
    Crvenkova S; Pesevska M
    J BUON; 2015; 20(3):775-81. PubMed ID: 26214630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of different chemotherapy regimens for concurrent chemoradiotherapy on locally advanced non-small cell lung cancer].
    Ren H; Wang LH; Wang XZ; Lü JM; Ji W; Zhou ZM; Ou GF; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):143-7. PubMed ID: 19538894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer.
    Harris JP; Murphy JD; Hanlon AL; Le QT; Loo BW; Diehn M
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):872-84. PubMed ID: 24495591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Locally advanced non-small cell lung cancer: what is the optimal concurrent chemoradiation regimen?
    Videtic GM
    Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS32-7. PubMed ID: 22614963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.
    Strøm HH; Bremnes RM; Sundstrøm SH; Helbekkmo N; Aasebø U
    Clin Lung Cancer; 2015 May; 16(3):183-92. PubMed ID: 25481662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer.
    Sen F; Saglam EK; Toker A; Dilege S; Kizir A; Oral EN; Saip P; Sakallioglu B; Topuz E; Aydiner A
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1497-505. PubMed ID: 21499895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
    Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
    Bastos BR; Hatoum GF; Walker GR; Tolba K; Takita C; Gomez J; Santos ES; Lopes G; Raez LE
    J Thorac Oncol; 2010 Apr; 5(4):533-9. PubMed ID: 20357618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of local thoracic surgery in patients with stage IV non-small-cell lung cancer: A SEER-based analysis.
    Jia J; Guo B; Yang Z; Liu Y; Ga L; Xing G; Zhang S; Jin A; Ma R; Wang J
    Eur J Cancer; 2021 Feb; 144():326-340. PubMed ID: 33388490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
    von Verschuer U; Schnell R; Tessen HW; Eggert J; Binninger A; Spring L; Jänicke M; Marschner N;
    Lung Cancer; 2017 Oct; 112():216-224. PubMed ID: 28916198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.